Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1097

Shown on this page

Current sort

Live official records

Conditions: Pouchitis
Interventions: etrasimod, Placebo; Drug
Lead sponsor: Maia Kayal; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions: Ketamine Hydrochloride, Midazolam Hydrochloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more

Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Duarte, California • Irvine, California • La Jolla, California + 5 more

Conditions: Nephrolithiasis
Interventions: Floseal, Surgicel, Surgiflo, Balloon Tamponade; Device · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Interventions: Screening Method (SM), Screening and Communication Method (SCM); Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years to 30 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 68
States / cities: Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 103
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 5
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Single Fraction Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 223
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 180 more

Conditions: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Interventions: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging); Drug
Lead sponsor: Aktis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Duarte, California • Irvine, California • Miami, Florida + 10 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

Etrasimod as Prevention of Pouchitis

Ketamine for Methamphetamine Use Disorder

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Tract Closure in PCNL

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

About this Mount Sinai institution page